Press

Biotechnology: key to addressing the triple environmental crisis and achieving the Sustainable Development Goals

05/06/2024

Climate change · Bioeconomy · Circular economy

• Biotechnology addresses environmental challenges through bioremediation, the production of renewable energy, sustainable agriculture, or the reduction of greenhouse gas emissions.
• Biofuels are one of the main alternatives to mitigate the impact of climate change. Bioenergy and biofuels include alternatives such as biodiesel, bioethanol, biogas, biomethane, biohydrogen or biomass.
• Biotechnological solutions in biostimulants and biofertilizers allow mitigating the effects of climate change, making better use of nutrients.

AseBio

Collaboration, efficient management of intellectual property and creation of spin-offs, vital for technology transfer and a thriving innovation ecosystem

29/05/2024

Healthcare · Access to innovation

• AseBio has organized, within the framework of the XVII Annual Conference of Biomedical Research Technology Platforms (Barcelona), the debate entitled “Collaboration and transfer: the DNA of biomedical research”.
• Collaboration between the different links in the transfer chain is crucial. It is a key element in the creation and strengthening of the business fabric and, in Spain, it is fundamental for the development of the biotechnology sector.
• Strong intellectual property protection is essential for the competitiveness of companies, and spin-offs are particularly useful for attracting investment, strengthening links between academia and industry, and boosting job creation and economic growth.
   

AseBio

From precision farming to the insect industry: how biotechnology is responding to the global challenge of hunger

28/05/2024

Climate change · Agrifood · Food & feed · Agriculture · Animal health

• Biotechnology is a cornerstone for the agri-food industry and for transforming food systems, as well as for addressing the underlying causes of food security and malnutrition.
• Thanks to precision agriculture, farmers can apply the exact amount of water, fertilizers and pesticides needed, thus reducing waste and production costs
• The insect industry will reach an estimated global production of 870,000 tons by 2030 and employ more than 30,000 people. 

AseBio

Effective and flexible regulatory policies, increased investment in R&D, and social awareness are pending tasks for Spain in the development of the bioeconomy

16/05/2024

Agrifood · Agriculture · Bioeconomy · Circular economy

• During the celebration of the AseBio Investor Day 2024, several experts analyzed the challenges and opportunities of the bioeconomy sector in Spain.
• Since 2010, as part of the Europe 2020 Strategy, the bioeconomy has been identified as a key element for sustainable growth in Europe, with leading countries such as Finland or Germany.
• At the regulatory and political level, Spain has had the Integral Bioeconomy Strategy since 2015, but it has barely evolved over time and has not achieved a significant impact.
  
   

AseBio

Spanish biotechs raise 228 million euros in private financing in 2023

15/05/2024

Financing

• During the AseBio Investor Day, held on May 15th in San Sebastián, AseBio has revealed data on private financing collected in the AseBio 2023 Report.
• The AseBio 2023 Report, a leading publication in the Spanish biotechnology sector, will be presented on June 12th at the Rafael del Pino Foundation in Madrid.
• In its fifth edition, the AseBio Investor Day 2024 has brought together nearly 280 attendees from over 180 entities from 19 countries, including 70 investors from more than 55 investment firms.
  
   

AseBio

The synergy between biotechnology and immunology catalyzes the development of more effective vaccines and personalized immunological therapies: a new horizon for addressing autoimmune diseases, cancer, and infectious pathologies

29/04/2024

Healthcare · Access to innovation · Drug discovery · Innovative drugs · Personalized medicine · Advanced therapies

• Biotechnology has achieved significant advances in diagnosis and precision therapies, the production of biotechnological drugs, and the treatment and understanding of infectious, autoimmune, and cancer diseases, among other areas.
• CAR-T therapies or monoclonal antibodies, two major advances in recent years in the field of immunology, are examples of the great potential of biotechnological innovation.
   

AseBio

Biotechnology and DNA: The duo paving the way for the era of customization in health and agriculture

25/04/2024

Healthcare · Access to innovation · Biosimilars · Personalized medicine · Advanced therapies · Gene editing

• Next-generation DNA sequencing has a significant impact on personalized medicine, genomic research, and the identification of genetic diseases.
• Genomic medicine is emerging as a central pillar of the future of healthcare, as the ability to personalize treatments based on each individual's genetics is transforming our approach to health.
• Genome editing has the potential to address real challenges for farmers and the planet, such as developing crops more resistant to diseases and the effects of climate change.

AseBio

AseBio launches the Food Innovation Working Group to boost the biotechnological potential of the Spanish agri-food sector

17/04/2024

Agrifood · Food & feed · Agriculture · Animal health

• The Spanish agri-food sector has undeniable strategic value for the national economy due to its impact on GDP: Spain ranks as the eighth global agri-food power.
• Within AseBio, over 25% of our members work in the agri-food sector, with presence across the entire value chain: from R&D phases to industrial stage.
• This group focuses its objectives on highlighting Spanish food innovation and Food tech, as well as driving food innovation to achieve recognition of new types of nutrients for both human and animal consumption.
  
   

AseBio

The "yes" from the European Parliament to the reform of pharmaceutical legislation jeopardizes biotechnological innovation if improvements are not introduced

12/04/2024

Healthcare · Access to innovation · Drug discovery · Innovative drugs · Personalized medicine · Advanced therapies · Antibiotic resistance

• We consider that improvements have been made regarding the original proposal, but these continue to be insufficient for the protection, development, and promotion of biotechnological innovation in Europe.
• Biotechnology has radically transformed the discovery of new drugs: 68% of the drugs currently in development globally are biotechnological.
• The GPL is not aligned with the European Commission, which has identified biotechnology as one of the key 'deep tech' areas for the future of the European Union and its strategic autonomy.
  
   

AseBio